Compare Enveric Biosciences Inc (ENVB) vs General Dynamics Corporation (GD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs General Dynamics Corporation — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.80M), while General Dynamics Corporation trades at $327.5 (market cap $89.26B). The key difference: General Dynamics Corporation is far larger — about 13126.5× Enveric Biosciences Inc's market cap, and General Dynamics Corporation pays a 1.93% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and General Dynamics Corporation for 85 Days on average.
| ENVB | GD | |
|---|---|---|
Market Cap | $6.80M | $89.26B |
Volume | 64,867 | 1,496,273 |
Sector | Health | Industrials |
52-Week High | $10.80 | $395.97 |
52-Week Low | $1.27 | $312.53 |
Typical Hold Time | 14 Days | 85 Days |
Enterprise Value | -$1.49M | $94.40B |
Dividend Yield | — | 1.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495 with a 1.7% daily gain, showing technical bearish signals despite recent earnings beats. The company reported no revenue in 2025 with significant losses (-$8.77M net income), though valuation metrics appear low (EV/EBITDA 0.17, P/B 0.84). Recent news highlights patent approvals and positive preclinical data for non-hallucinogenic therapeutics.
The outlook remains speculative given the lack of revenue and substantial losses, offset by strong analyst support (75% buy rating) and promising drug development progress. Key risks include funding needs and clinical trial outcomes, while institutional sentiment appears cautiously optimistic about long-term pipeline potential.
General Dynamics (GD) trades at $326.63, down 1.42% with bearish technical signals despite strong fundamentals. The defense contractor shows consistent revenue growth to $52.55B in 2025 and has beaten earnings estimates for three consecutive quarters. Analyst consensus remains strongly bullish with a $420.57 price target, supported by robust Pentagon spending and dividend reliability. Technical indicators show oversold conditions with RSI at 11.03, though moving averages signal bearish momentum.
GD presents a compelling value opportunity with attractive valuation metrics (P/E 19.92) and strong cash flow generation. Key risks include defense budget volatility and execution challenges, but the company's record backlog and dividend stability provide downside protection. The stock offers 28% upside to consensus targets with defensive characteristics suitable for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About General Dynamics Corporation
General Dynamics is a defense contractor and business jet manufacturer. The firm's segments include aerospace, combat systems, marine, and technologies. The company's aerospace segment creates Gulfstream business jets. Combat system produces land-based combat vehicles, such as the M1 Abrams tank. The marine subsegment creates nuclear-powered submarines, among other things. The technologies segment contains two main units, an IT business that primarily serves the government market and a mission systems business that focuses on products that provide command, control, computers, intelligence, surveillance, and reconnaissance capabilities to the military.
Read more on GD →
